Domvanalimab

Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used for studies of non-small cell lung cancer and esophageal cancer[1][2][3].

Product Specifications

CAS Number

[2368219-35-4]

Product Name Alternative

AB154

UNSPSC

12352203

Target

Transmembrane Glycoprotein

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/domvanalimab.html

Purity

96.41

Solubility

10 mM in DMSO

Smiles

[Domvanalimab]

Molecular Weight

(145.12 kDa)

References & Citations

[1]Dolgin E. Antibody engineers seek optimal drug targeting TIGIT checkpoint. Nat Biotechnol. 2020 Sep;38 (9) :1007-1009.|[2]Zhang Y, et al. Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy. Cell Res. 2019 Aug;29 (8) :609-627.|[3]Anderson A E, et al. Characterization of AB154, a humanized anti-TIGIT antibody, for use in combination studies. Cancer Research, 2019, 79 (13_Supplement) : 1557-1557.